Specific Antiviral Drugs For COVID 19 Market Opportunities Are Emerging Beyond Traditional Growth Areas
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Specific Antiviral Drugs For COVID 19 Market Size And Revenue Forecast Through 2030
The market for specific antiviral drugs targeting COVID-19 has experienced notable expansion in recent years, climbing from $15.23 billion in 2025 to an estimated $17.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.1%. This historical growth was driven by several key factors, including the swift transmission of the COVID-19 virus, the granting of emergency use authorizations, a dependence on established antiviral drug categories, constrained manufacturing capabilities on a global scale, and elevated rates of hospitalization.
The market for specific antiviral drugs targeting COVID-19 is anticipated to experience significant expansion in the coming years. It is projected to reach $33.17 billion by 2030, achieving a compound annual growth rate (CAGR) of 16.8%. Growth during this forecast period is driven by factors such as the creation of advanced antiviral agents, enhanced collaborations between public and private sectors, greater uptake of preventive treatments, broader use of combination therapies, and the incorporation of personalized medicine strategies. Key trends shaping this period include heightened investment in the creation of COVID-19 antiviral drugs, a surge in the use of oral antiviral tablets, progress in monoclonal antibody treatments, wider availability through hospital and retail pharmacy networks, and a greater emphasis on specific treatments for hospitalized and high-risk individuals.
Download A Free Sample Report For Comprehensive Market Insights:
Specific Antiviral Drugs For COVID 19 Market Demand Drivers Creating New Revenue Opportunities
The anticipated growth of the specific antiviral drugs market for COVID-19 is being driven by the increasing number of confirmed cases. These cases represent individuals who have tested positive for SARS-CoV-2, the virus responsible for COVID-19. This surge in infections is largely attributed to newly emerging variants that are more transmissible and possess the ability to partially bypass immunity gained from prior vaccinations or previous infections. Antiviral medications specifically designed for COVID-19 play a crucial role in lessening the severity and shortening the duration of the illness, which enhances patient recovery and reduces the overall strain caused by the pandemic. To illustrate, data released by the World Health Organization—a global public health body based in Switzerland—in May 2025 showed that the test positivity rate in the Eastern Mediterranean region surged from 4% to 17% during early 2025, exceeding figures recorded in the corresponding period of 2024. Consequently, the escalating number of COVID-19 cases is fueling expansion in the specific antiviral drugs market for this disease.
Specific Antiviral Drugs For COVID 19 Market Segment Landscape And Growth Potential
The specific antiviral drugs for covid 19 market covered in this report is segmented –
1) By Type: Tablet, Injection
2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment
3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies
4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets
2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections
Specific Antiviral Drugs For COVID 19 Market Trends Driving Strategic Industry Expansion
Key players within the specific antiviral drugs market for COVID-19 are concentrating on creating novel treatments, particularly oral antiviral therapies, aimed at improving both accessibility and effectiveness of care. These oral antiviral agents, ingested as pills, function by stopping the replication of viruses such as COVID-19, providing a convenient and efficient therapeutic approach. In March 2024, for example, Shionogi & Co., a pharmaceutical firm based in Japan, introduced Xocova and secured full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Moreover, this drug serves as a post-exposure prophylaxis, notably lowering the likelihood of developing symptomatic COVID-19 among exposed individuals while also decreasing symptom duration and maintaining a favorable safety profile.
Specific Antiviral Drugs For COVID 19 Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.
Access The Complete Specific Antiviral Drugs For COVID 19 Market Report:
Specific Antiviral Drugs For COVID 19 Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
